Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy. Biomol Biomed [Internet]. 2024 Jul. 28 [cited 2025 Apr. 16];24(4):673–675. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10641